The amazing and inspiring Vincent DeVita, MD, professor of medicine at Yale Cancer Center and former president of ACS, former Physician-in-Chief of MSKCC, and someone who has held way too many national titles to count, debated with me some of the ideas laid out in his book, “The Death of Cancer,” most notably the utility of randomized controlled trials in regulatory approvals.
As a lymphoma specialist, this episode was a highlight of my podcasting career; speaking with a legend that I have always admired from afar. What a treat. Listen and let me know what you think.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
